Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Improved Survival of Patients with Primary Plasma Cell Leukemia with VRD or Daratumumab-Based Quadruplets: A Multicenter Study By the Greek Myeloma Study Group

Blood (2022) 140 (Supplement 1): 4386–4387.

https://doi.org/10.1182/blood-2022-163065

Published: 2022

Journal Articles

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-138390

Published: 2020

Journal Articles

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Blood (2018) 132 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2018-99-115725

Published: 2018

Journal Articles

Demographic, Clinical and Laboratory Features, Management and Outcome of Immune Thrombocytopenia (ITP) in Greece: The National ITP Registry of the Hellenic Society of Hematology

Blood (2017) 130 (Supplement 1): 4859.

https://doi.org/10.1182/blood.V130.Suppl_1.4859.4859

Published: 2017

Journal Articles

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

Argiris Symeonidis, MD PhD, Alexandra Kourakli, MD, Ioannis Kotsianidis, MD PhD, Panagiotis Zikos, Eleftheria Hatzimichael, Theodoros Vassilakopoulos, MDPhD, Aikaterini Palla, Vassiliki Pappa, MD, Evgenia Verigou, Zafeirios Kartasis, MD, Eirini Katodritou, Maria Pagoni, Theodora Assimakopoulou, Charalampos Pontikoglou, MD PhD, Maria Dimou, George Xanthopoulidis, Maria K. Angelopoulou, MD, Maria Kotsopoulou, Dimitra Liapi, Despina Mparmparousi, Evridiki Michali, Anna Kioumi, Nora-Athina Viniou, Achilles Anagnostopoulos, Vassiliki Labropoulou, Maria Dalekou, Michael Voulgarelis, MD PhD, Efthymia Vlachaki, Anna Christoforidou, Ioannis Adamopoulos, MD, Akrivi Kostourou, Petros Laos, Evangelos Terpos, MD PhD, Eleni Kapsali, George Vassilopoulos, MD PhD, Helen A. Papadaki, MD PhD, Panayiotis Panayiotidis, MD PhD, Athanasios Galanopoulos, MD PhD

Blood (2017) 130 (Supplement 1): 1696.

https://doi.org/10.1182/blood.V130.Suppl_1.1696.1696

Published: 2017

Journal Articles

AML Survival and In Vivo Progression Is Dependent On β-Catenin Signaling.

Elena K Siapati, PhD, Magda Papadaki, MSc, Zoi Kozaou, Erasmia Rouka, Evridiki Michali, MD, Dimitrios Gogos, Ioanna Savvidou, Despoina S Kyriakou, MD, PhD, Nikolaos.I. Anagnostopoulos, George Vassilopoulos, MD, PhD

Blood (2009) 114 (22): 2398.

https://doi.org/10.1182/blood.V114.22.2398.2398

Published: 2009

Journal Articles

Prognostic Value of Minimal Residual Disease (MRD) Detection in Adult Acute Lymphoblastic Leukemia (ALL) – HYPER-CVAD Protocol

Nikolaos Tsagarakis, Nektaria Kentrou, Mirsini Pergaminou, Theodore Marinakis, Stefanos I Papadhimitriou, Georgios Gortzolidis, Athanasios Galanopoulos, Evridiki Michali, Konstantinos Papadimitriou, Dimitra Skoumi, Nikolaos Anagnostopoulos, Georgios Paterakis

Blood (2008) 112 (11): 4870.

https://doi.org/10.1182/blood.V112.11.4870.4870

Published: 2008

Journal Articles

Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG)

Efstathios Kastritis, Konstantinos Zervas, Argiris Symeonidis, Evangelos Terpos, Sossana Delimpassi, Nicolaos Anagnostopoulos, Evridiki Michali, Athanasios Zomas, Irini Katodritou, Dimitra Gika, Anastasia Pouli, Dimitrios Christoulas, Maria Roussou, Theofanis Economopoulos, Meletios A Dimopoulos

Blood (2008) 112 (11): 655.

https://doi.org/10.1182/blood.V112.11.655.655

Published: 2008

Journal Articles

The International Prognostic Scoring System for Waldestrom’s Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens.

Meletios Athanasios Dimopoulos, MD, Efstathios Kastritis, MD, Dimitra Gika, Sossana Delimpassi, MD, Konstantinos Zervas, MD, Argiris Simeonidis, MD, Evangelos Eleftherakis-Papaiakovou, MD, Nicolaos Anagnostopoulos, MD, Evridiki Michali, MD, Marie Christine Kyrtsonis, MD, Evangelos Terpos, MD, Gerassimos Pangalis, MD

Blood (2007) 110 (11): 3615.

https://doi.org/10.1182/blood.V110.11.3615.3615

Published: 2007

Journal Articles

The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma.

Meletios A. Dimopoulos, Konstantinos Anargyrou, Eirini Katodritou, Efstathios Kastritis, Anastasia Pouli, Evridiki Michali, Evgenia Verrou, Anastasia Banti, Konstantinos Tsionos, Aikaterini Stefanoudaki, Konstantinos Zervas, Evangelos Terpos

Blood (2007) 110 (11): 1478.

https://doi.org/10.1182/blood.V110.11.1478.1478

Published: 2007

Journal Articles

Cystatin-C Is a Sensitive Marker of Renal Impairment with an Independent Predictive Value for Survival in Multiple Myeloma; Reduction Post Bortezomib Monotherapy.

Evangelos Terpos, Eirini Katodritou, Evangelos Tsiftsakis, Efstathios Kastritis, Anastasia Pouli, Dimitrios Christoulas, Evridiki Michali, Evgenia Verrou, Anastasia Banti, Konstantinos Tsionos, Meletios A. Dimopoulos, Konstantinos Zervas

Blood (2007) 110 (11): 1484.

https://doi.org/10.1182/blood.V110.11.1484.1484

Published: 2007

Journal Articles

Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece.

Michalis Michail, MD, Efstathios Kastritis, MD, Sossana Delimpassi, MD, Marie Christine Kyrtsonis, MD, Evridiki Michali, MD, Nicolaos Anagnostopoulos, MD, Konstantinos Zervas, MD, Eirini Katodritou, MD, Panagiotis Panagiotidis, MD, Natalia Tzenou, Gerassimos Pangalis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 4729.

https://doi.org/10.1182/blood.V110.11.4729.4729

Published: 2007

Journal Articles

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Meletios A. Dimopoulos, MD, Athanasios Anagnostopoulos, M.D., Marie Christine Kyrtsonis, M.D., Constantinos Tsatalas, M.D., Garyfallia Kokkini, M.D., Panagiotis Repoussis, M.D., Athanasios Zomas, M.D., Argiris Symeonidis, M.D., Evridiki Michali, M.D., Nikolaos Anagnostopoulos, M.D., Evangelos Terpos, M.D., Theophanis Economopoulos, M.D., Gerasimos Pangalis, M.D.

Blood (2006) 108 (11): 128.

https://doi.org/10.1182/blood.V108.11.128.128

Published: 2006

Journal Articles

Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).

Blood (2006) 108 (11): 2745.

https://doi.org/10.1182/blood.V108.11.2745.2745

Published: 2006

Journal Articles

Renal Failure in Multiple Myeloma: Incidence, Correlations and Prognostic Significance.

Vangelis Eleftherakis-Papaiakovou, MD, Athanasios Anagnostopoulos, M.D., Aristotelis Bamias, M.D., Dimitra Gika, Argiris Symeonidis, M.D., Anastasia Pouli, M.D., Nikolaos Anagnostopoulos, M.D., Konstantinos Zervas, M.D., Evridiki Michali, M.D., Efstathios Kastritis, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 5000.

https://doi.org/10.1182/blood.V108.11.5000.5000

Published: 2006

Journal Articles

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Meletios A. Dimopoulos, MD, Maria Christina Kyrtsonis, MD, Constantinos Tsatalas, MD, Garyfallia Kokkini, MD, Panagiotis Repoussis, MD, Athanasios Zomas, MD, Argiris Symeonidis, MD, Evridiki Michali, MD, Athanasios Anagnostopoulos, MD, Nikolaos Anagnostopoulos, MD, Theophanis Economopoulos, MD, Gerasimos Pangalis, MD

Blood (2004) 104 (11): 752.

https://doi.org/10.1182/blood.V104.11.752.752

Published: 2004

NARROW

Improved Survival of Patients with Primary Plasma Cell Leukemia with VRD or Daratumumab-Based Quadruplets: A Multicenter Study By the Greek Myeloma Study Group

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Demographic, Clinical and Laboratory Features, Management and Outcome of Immune Thrombocytopenia (ITP) in Greece: The National ITP Registry of the Hellenic Society of Hematology

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

AML Survival and In Vivo Progression Is Dependent On β-Catenin Signaling.

Prognostic Value of Minimal Residual Disease (MRD) Detection in Adult Acute Lymphoblastic Leukemia (ALL) – HYPER-CVAD Protocol

Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG)

The International Prognostic Scoring System for Waldestrom’s Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens.

The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma.

Cystatin-C Is a Sensitive Marker of Renal Impairment with an Independent Predictive Value for Survival in Multiple Myeloma; Reduction Post Bortezomib Monotherapy.

Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece.

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).

Renal Failure in Multiple Myeloma: Incidence, Correlations and Prognostic Significance.

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only